BioMarin nabs FDA review for dwarfism drug vosoritide, forgoes AdComm as it eyes 2021 approval

The FDA will hand down a decision on BioMarin’s rare disease drug vosoritide by Aug. 21 as it says there's no need for an advisory committee.

The U.S. regulator has accepted BioMarin’s NDA for vosoritide, the biopharma’s investigational, once-daily injection analog of C-type natriuretic peptide (CNP) for children